Clovis Oncology grows first-quarter loss year-over-year
BOULDER — Clovis Oncology Inc. (Nasdaq: CLVS) posted a first-quarter loss of $1.54 per share, missing analyst expectations by 18 cents.
Clovis grew its loss year-over-year from $58 million during the first quarter of 2017 to nearly $78 million in the first quarter of 2018.
Despite the earnings loss, Clovis had firstquarter revenue of $18.25 million, a year-over-year increase of 163 percent. The company beat expectations by $190,000. Sales are attributed to its main drug product, Rubraca.
SPONSORED CONTENT
Business Cares: April 2024
In Colorado, 1 in 3 women, 1 in 3 men and 1 in 2 transgender individuals will experience an attempted or completed sexual assault in their lifetime. During April, we recognize Sexual Assault Awareness Month with the hopes of increasing conversations about this very important issue.
Clovis expects to receive marketing approval from the European Commission later in May and plans to file a maintenance treatment application for ovarian cancer in Europe in the second quarter of 2018.
BOULDER — Clovis Oncology Inc. (Nasdaq: CLVS) posted a first-quarter loss of $1.54 per share, missing analyst expectations by 18 cents.
Clovis grew its loss year-over-year from $58 million during the first quarter of 2017 to nearly $78 million in the first quarter of 2018.
Despite the earnings loss, Clovis had firstquarter revenue of $18.25 million, a year-over-year increase of 163 percent. The company beat expectations by $190,000. Sales are attributed to its main drug product, Rubraca.
Clovis expects to receive marketing approval from the European Commission later in May and plans…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
